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ABSTRACT 
 
Background and Objectives: Shigella is an etiological agent of shigellosis. Antibiotic therapy has a critical role in decreas-
ing serious complications of shigellosis. The present study aimed to determine the multi-drug resistance strains and to detect 
fluoroquinolone related mutations.  
Materials and Methods: In this descriptive, cross sectional study, a total of 113 Shigella isolates were collected from 1280 
patients admitted to Bu-Ali hospital in Ardabil province during 2015-17. Antibiotic resistance pattern of isolates was evalu-
ated using Kirby Bauer method and finally, the MICs of ciprofloxacin were determined. In order to determine any mutations 
in QRDR region, parC and gyrA genes of resistant strains were amplified and sequenced. 
Results: Shigella spp. isolates were identified using ipaH amplification and rfc and wbgz genes were used for molecular 
detection of S. flexneri and S. soneii, respectively. Our results showed that the predominant species in Ardabil province was 
S. sonnei (69.91%). Most of isolates (82%) were resistant to trimethoprim/sulfamethoxazole (TMP/SMX); 51% were nali-
dixic acid resistant and 4.4% were floroquinolones resistant. All examined isolates were susceptible to imipenem (100%). 
Mutation in gyrA and parC genes were detected in all fluoroquinolone resistant isolates (5 isolates). Although, in this study 
the rate of resistance to ciprofloxacin was low, but in the lack of preventive strategy it will be a major challenge of public 
health in future.
Conclusion: This study provided information on the prevalence and antimicrobial susceptibility patterns of Shigella isolates 
in Ardabil province, Iran. Also this study showed a high-level of resistance to commonly used antibiotics among Shigella 
isolates.
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INTRODUCTION
 Shigella, a causative agent of bloody diarrhea, is 
a Gram-negative, non-motile bacillus that belongs to 
Enterobacteriacae family. Shigella genus including 
S. dysenteriae, S. flexneri, S. boydii and S. sonnei 
belong to A, B, C and D, serogroups, respectively. 
Shigellosis is a bacillary dysentery or invasive diar-
rhea that clinically manifested by watery or bloody 
diarrhea. This infection mostly transmitted through 
contaminated food and water. The disease caused by 
S. dysenteriae is very severe with high mortality and 
transmission rate that mostly predominant in devel-
oping countries (1, 2). In 2016, WHO estimated that 
http://ijm.tums.ac.ir
QUINOLONE RESISTANT SHIGELLA SPP.
IRAN. J. MICROBIOL.  Volume 11 Number 6 (December 2019) 496-501                497 http://ijm.tums.ac.ir
about 165 million shigellosis occur each year world-
wide (3). Malnutrition along with poor sanitation is 
the most important risk factors for increasing inci-
dence of the disease and raising the mortality rate. 
Epidemiological studies around world indicated that 
Shigella spp. is one of the six leading pathogen at-
tributed to life threatening in children. Therefore, 
early diagnosis and appropriate treatment of the 
disease plays a critical role in reducing the mortal-
ity rate. In the lack of effective antimicrobial treat-
ment, the risk onset of serious complications, the 
duration of illness and death dramatically increased. 
According to literature guidelines fluoroquinolones 
especially ciprofloxacin is the first line of treatment.
For multidrug resistance strain, pivmecillinam (am-
dinocillin pivoxil) and ceftriaxone are recommend-
ed. Azithromycin is the second-line therapy which 
is only prescribed for adult and is not recommended 
for children due to limited efficacy (4). Fluoroquino-
lone resistance in Shigella is correlated with multiple 
mechanisms including several mutations in quino-
lone resistance-determining region (QRDR), efflux 
pump and plasmid-mediated quinolone resistance 
(PMQR). QRDR encoding DNA gyrase (gyrA and 
gyrB genes) and topoisomerase IV (parC and parE 
genes) which among different resistance mecha-
nisms has a predominant role. Presence of any muta-
tion in these regions decrease binding of the drug to 
the enzyme-DNA complex. In fact, fluoroquinolones 
target two substantial bacterial enzymes including 
DNA gyrase and DNA topoisomerase IV which par-
ticipate in DNA amplification. Alteration or single 
amino acid changes in either of these enzymes leads 
to fluoroquinolone resistance. Amino acids located 
in GyrA and ParC subunits are the most important 
amino acids which are covalently bound to DNA in 
both enzymes (5). Therefore, mutation in these ami-
no acids is directly related to resistance to fluoro-
quinolones.
Identification of drug-resistant strains and their 
antibiotic resistance profile provide appropriate em-
pirical treatment that will help in better control of the 
infection in the region of the study (6, 7). In this re-
gard, in the present study, 113 isolates which was col-
lected from Bu-Ali hospital during 2015-2017 were 
analyzed and the presence of any mutations in gyrA 
and parC genes were determined (8).
 
MATERIALS AND METHODS
 Media and chemicals. For isolation of Shigella 
spp. different media such as selenite F broth, Hek-
toen enteric agar (HE), Xylose lysine deoxycholate 
agar (XLD) were used (Himedia laboratories, Mum-
bai, India). For PCR reaction, oligonucleotide prim-
ers were synthesized by Bioneer Company (Daejon, 
South Korea). Ciprofloxacin powders were purchased 
from Bio Basic Company (Bio Basic Inc. Canada) 
for Minimum inhibitory concentration (MIC) deter-
mination. The antibiotic discs were prepared from 
Padtanteb Company (Padtanteb, Iran) and species 
specific antisera were purchased from SIFIN (Sifin 
diagnostics gmbh, Germany).
 Bacterial isolates. In this descriptive, cross sec-
tional study, from 2015 to 2017, a total of 113 Shi-
gella isolates were collected from infected patients 
with <10 years old at Bu Ali hospital in Ardabil prov-
ince. All isolates were examined by microbiological 
tests such as Gram staining, colony morphology on 
HE, XLD and EMB media and also IMViC tests (9). 
Serotyping of all biochemical positive isolates were 
done using Shigella specific antiserum. Whole bac-
terial genome was extracted using boiling method as 
described previously (10). Also molecular confirma-
tion of Shigella spp, S. flexneri and S. sonnei were 
performed using amplification of ipaH, rfc and wbgz 
genes, respectively (Table 1). PCR reaction contain-
ing 10 pmol of each primer, MgCl2 1.5 mM, 0.2 mM 
each dNTP, 1U Taq DNA polythermase was prepared 
at the total volume of 20 μl.  Thermocycler program 
for PCR reaction was initial denaturation at 94°C for 
5 min, followed by 30 cycles; denaturation at 94°C 
for 1 min, annealing at 60°C for 1 min, elongation 
at 72°C for 3 min. results of PCR reaction were ana-
lyzed via gel electrophoresis (10, 11).
Antimicrobial susceptibility testing. General 
susceptibility test was done for ciprofloxacin (5 μg), 
nalidixic acid (30 μg), norfloxacin (10 μg), peroxazine 
(5 μg), gentamicin (10 μg), ceftriaxone (30 μg), cotri-
moxazole (30 μg), impenamine (30 μg), amikacin (30 
μg), and azithromycin (15 μg) using the disk diffusion 
method. E. coli ATCC-25922 and S. flexneri ATCC-
12022 were used as controls. Minimum inhibitory 
concentration (MIC) for ciprofloxacin were deter-
mined for all identified isolates using agar dilution 
method (concentration rang: 0.25-256 μg/ml) (12). 
PCR amplification and sequencing. The QRDRs 
http://ijm.tums.ac.ir
ROGHAyEH TEIMOURPOUR ET AL.                                                                                                         
498           IRAN. J. MICROBIOL.  Volume 11 Number 6 (December 2019) 496-501
Table 1. List of specific primers were used for amplification of ipaH, rfc, wbgz genes.
Gene name
ipaH
rfc
wbgz
gyrA
parC
Primer sequence
F    5′ GTTCCTTGACCGCCTTTCCGATACCGTC3′
R    5′ GCCGGTCAGCCACCCTCTGAGAGTAC3′
F    5′ TTTATGGCTTCTTTGTCGG3′
R    5′ CTGCGTGATCCGACCATG3′
F    5′ TCTGAATATGCCCTCTACGCT3′
R    5′GACAGAGCCCGAAGAACCG3′
F    5′ TACACCGGTCAACATTGA GG3′
R    5′ TTA ATGATTGCCGCCGTCGG3′
F    5′ GTCTGA ACT GGGCCTGAATGC3′
R    5′ AGCAGCTCGGAATATTTCGACAA3′
PCR product size
619 bp (15)
537 bp (16)
430 bp (16)
648 (17)
249 (17)
Annealing time°C
60
60
60
52
60
http://ijm.tums.ac.ir
of the gyrA and parC genes in clinical isolates were 
amplified using PCR technique and specific primers 
which are listed in Table 1. Extraction of genomic 
DNA from identified colonies was performed using 
boiling method (10). For all amplifications, a PCR 
mixture contains  1× PCR buffer, 1.5 mmol MgCl2, 
0.2 mM of each dNTP, 1U of Taq DNA polymerase, 
10 pmol of each primer, 1 µl of template DNA (0.5 
µg), and sterile distilled water up to 25 µl were used.
DNA amplification was done in the thermocycler 
PCR instrument (Bio Rad, USA). The temperature 
profile for parC and gyrA genes consisted of 95°C for 
1 min;  followed by 35 cycles denaturation at 95°C for 
of 30 sec, 30 sec of annealing at 52°C for gyrA and 
60°C for parC, and 1 min of extension at 72°C and 10 
min at  72°C for  final extension. PCR products were 
analyzed using gel electrophoresis (1% agarose gel 
and 0.5/l mg ethidium bromide) UV transilluminator 
(10, 11, 13, 14). 
PCR products of gyrA and parC genes relat-
ed to five fluoroquinolone resistant strains were 
sequenced (Macrogene, South Korea) and ac-
quired results were analyzed by DNAMAN, 
Chromas softwares and NCBI database 
(http:/www.ncbi.nlm.nih.gov/BLAST/) softwares.
 
Statistical analysis. Resistance patterns andsta-
tistical comparisons were analyzed using SPSS soft-
ware (version 20) and one-way ANOVA method.
RESULTS
   In the present study, a total of 113 Shigella isolates 
were recovered from patients with bacillary dysen-
tery admitted to Bu Ali hospital during 2015-17. Of 
them, 79 cases (69.9%) were Shigella sonnei, 22 cas-
es (19.4%) were Shigella flexneri, 9 cases (9.9%), Shi-
gella boydii and 3 cases (6.2%) were Shigella dysen-
teriae. It was revealed that the dominant species in 
the Ardabil area is Shigella sonnei. Antimicrobial 
susceptibility test showed that 82% and 50.4% of iso-
lates were resistant to co-trimoxazole and nalidixic 
acid respectively, but all (100%) were susceptible to 
imipenem. The rate of resistance to fluoroquinolones 
including ciprofloxacin, norfloxacin, ofloxacin was 
4.4% (Table 2). Of the 113 identified strains, only 
5 cases (4.4%) were resistant to ciprofloxacin. The 
MIC values for ciprofloxacin were determined for all 
identified strains that were in the range of 0.25 to 256 
μg/ml. The MIC of ciprofloxacin against 90 isolates 
was less than 0.25 μg / ml, for 12 isolates was 0.5 
Table 2. Resistance pattern of Shigella isolates collected 
from clinical specimens of Bu Ali Hospital in Ardabil, Iran
Antibiotics
Ciprofloxacin
Ofloxacin
Norfloxacin
Nalidixic acid
Cotrimoxazole
Imipenem
Amikacin
Gentamicin
Ceftriaxone
Azithromycin
Resistance
5 (4.4%)
5 (4.4%)
5 (4.4%)
57 (50.4%)
93 (82%)
-
15 (13.3%)
22 (19.4%)
33 (29%)
16 (14.2%)
Intermediate
-
-
-
6 (5.4%)
5 (4.7%)
-
2 (1.7%)
5 (4.4%)
6 (5%)
10 (8.8%)
Susceptible
108 (95.6%)
108 (95.6%)
108 (95.6%)
50 (44.2%)
15 (13.3%)
113 (100%)
96 (85%)
86 (76.2%)
74 (66%)
87 (77%)
Shigella spp. N= 113 
N (%)
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Table 3. Alterations in gyrA and parC in clinical Shigella isolates
No. of 
strains
9 (S. boydii)
21 (S.boydii)
47 (S. sonnei)
63 (S. sonnei)
68 (S. sonnei)
MICs 
(μg/ml) 
CIP*
128
32
16
16
16
gyrA position
Ser83 (TCG)
Leu (TTG)
Leu (TTG)
Leu (TTG)
Leu (TTG)
Leu (TTG)
Asp87 (GAC)
Asn (AAC)
Asn (AAC)
Gly (GGC)
Gly (GGC)
Gly (GGC)
Glu210 (GAA)
-
-
Gln (CAA)
Gln (CAA)
Gln (CAA)
Pro213 (CCG)
Arg (CGG)
Arg (CGG)
Arg (CGG)
Arg (CGG)
Arg (CGG)
Ser80 (AGC)
Ile (ATC)
Ile (ATC)
Ile (ATC)
Ile (ATC)
Ile (ATC)
Tyr128 (TAT)
-
-
-
Phe (TTT)
Phe (TTT)
Ser129 (TCC)
-
-
-
PRO (CCC)
PRO (CCC)
parC position
Nucleotide and amino acid change
*ciprofloxacin
μg/ml, 6 isolates was 1 μg/ml. Five isolates showed 
high level of resistance to ciprofloxacin. MIC for 3 
cases (Shigella sonnei) was 16 μg/ml, 1 case (Shigel-
la boydii) was 32 μg/ml and 1 case (Shigella boydii) 
128 μg/ml. To determine any changes in the struc-
ture of DNA gyrase and topoisomerase IV enzymes, 
the QRDRs of corresponding genes (gyrA and parC) 
were amplified and sequenced.
   Nucleotide sequence of DNA gyrase subunit A 
(accession no. ARS04283.1) and DNA topoisomerase 
IV subunit A (WP_001281839.1) were used for pro-
tein alignment.
    In the case of gyrA gene, sequence analysis re-
vealed that all five ciprofloxacin resistant isolates 
(100%) had Ser83Leu, Asp87Gly/Asn and Pro213Arg 
substitution. Glu210Gln only was seen in Shigella 
sonnei resistant strains. For the parC gene, all five 
ciprofloxacin resistant isolates carried Ser80Ile mu-
tation while Tyr128Phe and Ser129Pro substitutions 
were detected in Shigella boydii resistant strains (Ta-
ble 3). 
DISCUSSION
   In 2016, Shigella was the second leading cause of 
diarrhea-related deaths (18). Among different species 
of Shigella, S. dysenteriae is more severe and is more 
associated with other life-threatening complications 
such as haemolytic-uraemic syndrome (19). based on 
previous reports along with our study, this species is 
rare in Iran (20). 
   In contrast to other studies which indicated that S. 
flexneri is predominant species in developing coun-
try, the current study indicated that S. sonnei is the 
most common causative agent of shigellosis in Ard-
abil region which has been consisted with other stud-
ies (21). Also, in another study in Gorgan, S. sonnei 
was reported as a dominant species. Actually, the 
proximity of these two regions to each other may be 
the reason for this similarity. However, in the south-
ern regions, the prevalence of S. flexneri is higher 
than other parts. In fact, the geographical regions, 
socio economic condition and personal hygiene af-
fect the prevalence of Shigella species (22, 23).  
    In this study the highest rate of antibiotic resistance 
was related to co-trimoxazole (93%) which indicat-
ed that this antibiotic is not suitable for treatment 
of shigellosis. This rate was in accordance with the 
previous studies from Iran (21, 24). Although co-tri-
moxazole has been used extensively in the treatment 
of diarrhea, but overuse of it has led to a high degree 
of resistance.
    The rate of resistance to nalidixic acid (57%) was 
relatively high in compare with previous dtudy (25). 
Therefore, it can be concluded that the administra-
tion of co-trimoxazole and nalidixic acid should be 
limited. Also it should be noted that the results of 
previous studies indicated that resistance to nalidix-
ic acid was on the rise in Iran (21, 26, 27) which is 
in agreement with our result. Although fluoroquino-
lones and azithromycin are effective drugs, but de-
creased susceptibility to azithromycin have been de-
scribed by Centers for Disease Control and Preven-
tion (CDC) (1). Therefore surveillance of antibiotic 
resistance and appropriate use of available antibiotic 
are recommended.
   Ciprofloxacin resistance rate (4.4%) of our study 
was close to a similar study in Tabriz (4.2%), located 
in proximity of Ardabil. In the present work, 5 iso-
lates had high MIC for ciprofloxacin, of them, two 
isolates were S. boydii and the rests were S. sonnei. 
The MIC value in S. boydii was significantly higher 
than S. sonnei (Table 3). Although currently, these 
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isolates are very rare but they could be pose as a se-
rious concern in future.
   According to previous studies, it is accepted that 
two or more mutations in both gyrA and parC sub-
units, especially at the highly conserved amino acids 
(Ser-83 and Asp-87) of gyrA, changes the structure of 
the DNA gyrase and DNA topoisomerase IV which 
are necessary to obtain moderate to high-level of re-
sistance to ciprofloxacin (18, 28). Our sequencing re-
sults revealed that Shigella isolates with MIC greater 
than 16 µg/mL carried at least four mutations in gyrA 
(83, 87, 210, 213 codon) and parC (80, 128, 129 co-
don) genes. These results indicate that all of these 
changes are related to point mutations that resulted in 
substitution of several amino acids at GyrA and ParC 
subunits which ultimately reduced drug affinity to its 
target and high-level fluoroquinolone resistance (29). 
However, in one isolate with the highest MIC (128 
µg/mL), other resistance mechanism such as efflux 
pump may be involved that needs to be investigat-
ed. In a study conducted by Ranjbar in Tehran, in 
two nalidixic acid-resistant Shigella strains, only one 
Ser83Leu mutation was observed (30). In anoth-
er study, Yaghoubi et al. reported D87Y mutation 
that was not found in our work (31). However, they 
showed all ciprofloxacin-resistant isolates (MIC>32 
mg/ml) had mutation in gyrA and parC genes at po-
sitions Ser83Leu/Asp87Gly and Ser80Ile respective-
ly. In this study the most common mutations in gyrA 
and parC genes were Ser83Leu and Ser80Ile, rela-
tively as seen in previous study in China (32). To our 
knowledge, other mutations including Glu210Gln 
and Pro213Arg substitutions are unique in the pres-
ent work. The hallmark of the present study was to 
demonstrate the correlation of high-level of resis-
tance to ciprofloxacin and rising MIC and several 
mutations in gyrA and parC genes during 2015-2017. 
Research over the past few years have shown that 
Shigella spp. have become resistant to formerly ef-
fective drugs and misuse of potent available antibiot-
ics such as fluoroquinolones may repeat this scenario 
not so long ago (33, 34).
   In conclusion, this study described fluoroquino-
lone resistance among Shigella spp. isolates collect-
ed from Ardabil province of Iran in 2015-2017. Our 
results provides valuable information in antibiotic 
resistant pattern of indigenous strains and suggest 
that acquisition of mutations in gyrA and parC genes 
plays a critical role in the development of high-level 
resistance to fluoroquinolones.
CONCLUSION
    This study provides baseline information on the 
prevalence of Shigella species on Ardabil province, 
antibiotic resistance pattern of isolates and associa-
tion of the fluoroquinolone resistance with different 
mutations in QRDR region. These data will helpful in 
elucidating molecular mechanisms of drug resistance, 
development of new strategies to control the emergence 
and spread of MDR strain and providing appropriate 
empirical therapy against Shigella infections.
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